Relapsed/Refractory Leukemias
2 clinical trials · Condition
◉ Watch Relapsed/Refractory Leukemias
| Record | Firm | Date |
|---|---|---|
| A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia (NCT05326516) | Syndax Pharmaceuticals | 2022-03-09 |
| Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias (NCT01239108) | Astex Pharmaceuticals, Inc. | 2010-10-01 |
Track Relapsed/Refractory Leukemias automatically
Every clearance here is in the API, with alerts when new ones post.